TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in NT-pro-BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of exercise capacity (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of work efficiency (Powermax/VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intention-to-treat cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychomotor speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post operative infection
Endpoint domain: Adverse events/effects
Primary endpoint: recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Cultural competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of 3-NT in sputum supernatant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of 3-NT positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil cell counts in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: intima-media thickness of the carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: number of hemodynamically significant stenoses in the aortotibial tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: gains in coping efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk of dementia
Endpoint domain: Mortality/survival
Primary endpoint: Alteration of oral microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of 6-month MACE
Endpoint domain: Mortality/survival
Primary endpoint: Mean peak CPK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular performance parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding risks
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of nerve axon reflex-related vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anti-HCV antibodies in diabetic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Preoperative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: anxiety at the time of biopsy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk of recurrence of verified and probable HSV‐2 meningitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dyspnoea relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days in ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ICU cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hypoglycemia (< 3.3 mmol/L)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in gingival index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plaque index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in periodontal index (PBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic anastomotic leakage
Endpoint domain: Mortality/survival
Primary endpoint: Bowel movements per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall well-being owing to bowel function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: significant improvement in voiding diary, uroflow and DVSS questionnaires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of treatment sessions required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical well-being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to ulcer recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness using QALYs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained virological response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2/FiO2 ratio improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of survival with unassisted breathing for at least 48 consecutive hours at day 28
Endpoint domain: Mortality/survival
Primary endpoint: VEV (Visual Analog Scale for Emotional Wellbeing)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BDI (Beck Depression Inventory)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time from cardioversion to first episode recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Days alive and out of hospital (DAOH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Survival without hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from 12-month CD-TLR
Endpoint domain: Mortality/survival
Primary endpoint: Safety endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month CD-TVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mRNA expression of bFGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: placental malaria by histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: placental parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: all-cause mortality of infants at 6 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Severity of hallucinosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal muscle mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relationship satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SAD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratios of IFN-gamma/IL-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 50% reduction in fatigue VAS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Area under the receiver operating characteristic curve (AUC) for DVT detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: hospital cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time with severe withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bifidogenic effect on gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in butyrate-producing bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in gut microbiota structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pressure pain threshold and tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beneficial effect of losartan versus atenolol on cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: loss of bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Persistent rectal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical failure free survival (BFFS)
Endpoint domain: Mortality/survival
Primary endpoint: near point of convergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive fusional vergence at near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrimination of PEA-BP subjects from ADHD and CC controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lowering A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lowering FBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lowering weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum increase in sCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of CIN
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month quit rates
Endpoint domain: Mortality/survival
Primary endpoint: mean late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue impact
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AVNRT recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax of lmi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-infinity of lmi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of lmi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung cancer diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: percentage of appointment conflicts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinic utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Global Health Status (GHS)/HRQoL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: s-DHEAS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: low-dose ACTH test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HBV-DNA titer decrement to undetectable levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic period for HBV-DNA titer decrement (>2 log(10) IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Energy Expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV-DNA level below 20 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative genetic mutation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases in eGFR more than 30% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major Adverse Cardiac Events (MACE) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Improved identification of team members based on name
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved identification of team members based on role
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive patient feedback regarding coordination of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: positive pelvic urine culture
Endpoint domain: Adverse events/effects
Primary endpoint: positive stone culture
Endpoint domain: Adverse events/effects
Primary endpoint: endotoxemia
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incisional hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral nerve toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Medication discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Labor pain relief experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labor satisfaction memory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breastfeeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T lymphocytes (CD3+) expression of GCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Return to sports at preinjury level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ICRS Cartilage Repair Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 25 hydroxy vitamin D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in alveolar concentrations of IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Augmentation of respiratory burst capacity of AM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transient fever-reactions
Endpoint domain: Adverse events/effects
Primary endpoint: gait/daily living activity independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spasticity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: CIS20r fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Olfactory function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relative risk of BPD
Endpoint domain: Mortality/survival
Primary endpoint: Cleansing coefficient of the proximal bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completion of small bowel examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Final positive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Capturing a social history
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Developing an appropriate treatment plan
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Troponin T release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with normal stress MIBI SPECT study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CPR skills and performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected Distance Visual Acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial healing percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of haze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post‐partum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Vaginal operative delivery for fetal heart rate abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: total transection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left ventricular ejection fraction (LVEF) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular end-systolic volume (LVESV) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New York Heart Association (NYHA) functional class reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median urge incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deferment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical functioning domains of quality-of-life instruments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of HBV mutants associated with resistance to NAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of S protein antigenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-warfarin area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean PT AUC and Cmax ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: INR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: semantically cued memory retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hoarseness symptom alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sural nerve conduction velocity (SNCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean sensory latency (SNSL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glycohemoglobin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting blood glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systemic oxygenation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: increase in vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PDPH
Endpoint domain: Adverse events/effects
Primary endpoint: Need for EBP
Endpoint domain: Adverse events/effects
Primary endpoint: Time from ADP to occurrence of PDPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microleakage values between enamel and dentin sides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of persistent diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral component stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: calcar resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: OHS (Oxford Hip Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: in-stent very late luminal loss (VLLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: UAS7 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of parotid flow complications
Endpoint domain: Adverse events/effects